ANGLE PLC AGL

Latest Morningstar Commentary
Date	Author		Headline

Latest Company News

Date	Time	Source	Headline	Type
Previous Stories...
13/05/2013	16:00	DJ	DJ Blinkx Beats Revenue Expectations; Angle Sees Better Prospects for Parsortix	OUT
13/05/2013	12:30	DJ	DJ Blinkx Beats Revenue Expectations; Angle Sees Better Prospects for Parsortix	OUT
13/05/2013	09:38	DJ	DJ Angle Sees Better Prospects for Parsortix; Atlantic Coal Ends Option Talks	OUT
13/05/2013	09:37	DJ	DJ Angle Sees Better Prospects for Parsortix; Atlantic Coal Ends Option Talks	OUT
13/05/2013	08:28	DJ	DJ Angle Automates Cell Harvesting Function, Sales Prospects Significant	ERN
13/05/2013	07:00	RNS	Angle PLC - PARSORTIX CELL HARVESTING	MSC
07/05/2013	07:53	DJ	DJ Angle Appoints Specialist Firm to Obtain Authorizations Parsortix	OUT
07/05/2013	07:00	RNS	Angle PLC - Parsortix Regulatory Approval Update	MSC
28/02/2013	07:00	RNS	Angle PLC - Parsortix Research Product Launch	PRL
15/02/2013	10:56	RNS	Angle PLC - Director's share transfer	RDS
31/01/2013	16:00	DJ	DJ Rank in Talks to Amend Deal with Gala Coral, Angle Eyes Profit	OUT
31/01/2013	12:30	DJ	DJ Scancell Holding 1H Loss Widens, N Brown Names New CEO	OUT
31/01/2013	12:26	DJ	DJ Angle Expects Significant Profit in Fiscal 2015	OUT
31/01/2013	09:30	DJ	DJ N Brown, Dechra Pharmaceuticals and Pochin's Announce Board Changes	OUT
31/01/2013	07:59	DJ	DJ Angle Raises GBP2.3M	OUT
31/01/2013	07:48	DJ	DJ Angle Reports Narrowed Half Year Loss	Div
31/01/2013	07:01	RNS	Angle PLC - Fundraising and Director's Dealings	MSC
31/01/2013	07:00	RNS	Angle PLC - Interim Results	IR
16/01/2013	07:00	RNS	Angle PLC - Notification of Interim Results and Webcast	MSC
15/01/2013	16:00	DJ	DJ Michael Page to Open Offices in Asia, Latin America	OUT

Regulatory News Abstract
Date	Type	Story
13/05/2013	Business Event	Parsortix cell harvesting The company has further extended the operational capability of its Parsortix non-invasive cancer diagnostic product by automating its cell harvesting function. The Parsortix system now has the potential to provide users with cancer cells for analysis from a simple blood test a form of "liquid biopsy"
07/05/2013	Business Event	Parsortix regulatory approval update The company announces the appointment of a specialist regulatory company, Medical Device Management, to manage the process of obtaining regulatory authorisations for the clinical use of the Parsortix cell separation system
28/02/2013	Business Event	Parsortix Research Product The company has initiated the launch of its Parsortix non-invasive cancer diagnostic product for the research market.
31/01/2013	Corporate Action	Fundraising of shares The company has successfully completed a fundraising of up to £2.20m net of costs. Investors will acquire up to 4.53m new Ords of 10.0p per share in the company at a price of 50.0p per share representing a discount of 17.4% on the mid price of 60.5p per share at close of business on 30 January 2013. The allotment of the fundraising shares, which is under existing authorities, is conditional on admission of the fundraising shares to trading on AIM becoming effective in accordance with the AIM Rules for Companies. It is expected that the fundraising shares to be issued to EIS and VCT qualifying investors being 1.78m shares will be admitted to trading on AIM and dealings will commence no earlier than on 7 February 2013 and 2.75m shares will be admitted to trading on AIM and dealings will commence no earlier than on 8 February 2013
31/01/2013	Trading Statement	no outlook statement no outlook statement
15/01/2013	Disposal	Acolyte Biomedica Settlement The company has received a settlement payment in respect of the deferred consideration due on the sale of its portfolio company Acolyte Biomedica Ltd. The company has recieved 0.29m which is slightly more than the figure of £0.15 relating to the deferred consideration
14/01/2013	Business Event	Parsortix Cell Recovery The company has achieved a major new breakthrough in the potential use of its Parsortix non-invasive cancer diagnostic product. In addition to the technology's ability to capture and count very rare circulating tumour cells from the blood of cancer patients, the company has developed a process for recovering captured cells from the Parsortix cassette
07/01/2013	Non-Exec Director Change	Brian Howlett appointed Brian Howlett has been appointed to the board as non-executive director with immediate effect

Welcome to Morningstar.co.uk!

For more information:

ANGLE PLC AGL

Latest Company News